This document discusses principles of radiobiology including types of radiation, how radiation causes biological effects, and factors that affect radiobiological outcomes. It covers topics like linear energy transfer, relative biological effectiveness, oxygen enhancement ratio, and how tissue factors like the cell cycle, chromatin structure, and regeneration influence radiation responses in normal and tumor tissues. The key aims are to understand how radiation damages cells and tissues at the molecular, cellular, and physiological levels and how these principles apply clinically in areas like radiation therapy fractionation schedules and the risks of reirradiation.
Focus on radiation types, effects, mechanisms, and pivotal concepts like LET, RBE, and OER. Discuss ionization, biological impacts of ROS, and comparative effectiveness of various radiation.
Focus on radiation types, effects, mechanisms, and pivotal concepts like LET, RBE, and OER. Discuss ionization, biological impacts of ROS, and comparative effectiveness of various radiation.
Focus on radiation types, effects, mechanisms, and pivotal concepts like LET, RBE, and OER. Discuss ionization, biological impacts of ROS, and comparative effectiveness of various radiation.
Focus on radiation types, effects, mechanisms, and pivotal concepts like LET, RBE, and OER. Discuss ionization, biological impacts of ROS, and comparative effectiveness of various radiation.
Focus on radiation types, effects, mechanisms, and pivotal concepts like LET, RBE, and OER. Discuss ionization, biological impacts of ROS, and comparative effectiveness of various radiation.
Focus on radiation types, effects, mechanisms, and pivotal concepts like LET, RBE, and OER. Discuss ionization, biological impacts of ROS, and comparative effectiveness of various radiation.
Examine tissue responses to irradiation, cell cycle effects, repair mechanisms, and damage types. Discuss acute vs late responding tissues and implications for radiation therapy.
Examine tissue responses to irradiation, cell cycle effects, repair mechanisms, and damage types. Discuss acute vs late responding tissues and implications for radiation therapy.
Examine tissue responses to irradiation, cell cycle effects, repair mechanisms, and damage types. Discuss acute vs late responding tissues and implications for radiation therapy.
Examine tissue responses to irradiation, cell cycle effects, repair mechanisms, and damage types. Discuss acute vs late responding tissues and implications for radiation therapy.
Analysis of latency and tolerance in tissues, focusing on gut sensitivity and factors that influence recovery. Clinical implications of regeneration strategies in radiation therapy.
Analysis of latency and tolerance in tissues, focusing on gut sensitivity and factors that influence recovery. Clinical implications of regeneration strategies in radiation therapy.
Analysis of latency and tolerance in tissues, focusing on gut sensitivity and factors that influence recovery. Clinical implications of regeneration strategies in radiation therapy.Introduction to reirradiation concepts, objectives related to head and neck cancer. Discuss challenges and advancements in radiation techniques.
Different approaches for treating recurrent tumors, detailing surgical, chemotherapy, and radiotherapy options. Analyze side effects and response rates associated with reirradiation.
Different approaches for treating recurrent tumors, detailing surgical, chemotherapy, and radiotherapy options. Analyze side effects and response rates associated with reirradiation.
Evaluate re-treatment in peripheral bone and spine metastasis, focusing on criteria for retreatment and outcomes with Stereotactic body radiation therapy (SBRT).
Overview of glioma treatment standards and reirradiation challenges. Techniques like conformal radiotherapy and stereotactic radiosurgery are discussed for effective targeting.
Overview of glioma treatment standards and reirradiation challenges. Techniques like conformal radiotherapy and stereotactic radiosurgery are discussed for effective targeting.
Reirradiation ; Backgroundstate of art
and prespective
part I : Principles Of Radiobiology
By
Ereny S. Poles
Ass.lecutrer of clinical oncology, Assuit university
10-9 10-8 10-710-6 10-5 10-4 10-3 10-2 10-1 1 10 102 103 104
rays
X-rays U.V.
v
i
s
i
b
l
e
Infra Red Radio Waves
Microwaves Short Waves
T.V.
Radio
Radar
IONIZING
RADIATION
NON-IONIZING RADIATION
(cms)
E (eV) 1.24x107 1.24x102 1.24x10-13
ELECTROMAGNETIC RADIATIONS
Photon E = h(energy = Planck’s const x frequency)
= hc/ (c = speed of light, = wave length)
6.
Ionizing radiation hasenough kinetic energy
to detach at least one electron from an
atom or molecule, creating ions
Charged particles such as electrons, protons,
heavy ions, alpha and beta particles are
directly ionizing because they can interact
directly with atomic electrons.
In contrast, photons (x rays, rays) and
neutrons are chargeless and therefore
more penetrating. They are indirectly
ionizing.
7.
What we wantto penetrate????
What is our target
??????
11.
What is thebiological effect of radiation
How it works
*Biological effects of ionizing radiation are determined in large part
by free radical
*Since H2O is the major component in cells, the most common ionization
event is radiolysis of water, producing reactive oxygen species (ROS)
The most relevant water is within 2nm of the DNA and tightly bound
*ROS produced include: H. - reducing; OH. - oxidizing; HO2
. - oxidizing
(O2 + H.); H2O2 - oxidizing
The net effect is oxidation of cellular constituents
About 60% of DNA damage caused by x-rays is due to ROS
About 75% of the indirect action of radiation is due to hydroxyl
radicals (OH.)
Ionization produces ions,ion radicals, and free radicals
concentrated along tracks and especially at Bragg peak of
primary and secondary electrons. They are highly reactive
and cause damage to biological matter
Ion formation – H2O+ and e-
Excitation and H and OH radical formation
ION RADICAL LIFETIME
FREE RADICAL LIFETIME
BREAKAGE OF BONDS
CHEMICAL REPAIR / MISREPAIR
ENZYMIC REPAIR / MISREPAIR
EARLY BIOLOGICAL EFFECTS
LATE BIOLOGICAL EFFECTS
10-18
10-12
10-6
100
106
SECS
Absorption of energy
Physical effects
Chemical lesions
Chemical repair
Enzyme repair/lesion
Cellular effects Tissue
effects Systemic effect
Hrs-Days
Mins-Hrs
10-16
10-14
15.
10MvGamma
rays
10MvProton ,
Neutron
The Grayis the Physical Unit of Radiation
• 1 GRAY, the unit of absorbed dose (1 joule / Kg),
– Causes 1-2 x 105 ionization events / cell
– 1% in DNA
– A single cobalt 60 ray will deposit about 1mGy in a cell
• Rad (Radiation Absorbed Dose) is the old unit = cGy
Physical Factors OfRadiation Affect
Radiobiological Effect:
1.Linear Energy transfer ( LET)
2.Relative Biological Effectivness (RBE)
3.Oxygen Enhancement Ratio (OER)
18.
1- Linear EnergyTransfer:
LET is average energy (dE) imparted by excitation
and Ionization events caused by a charged particle
traveling a set distance (dl) -
LET = dE/dl (keV/ m)
20.
gamma rays
deep therapy
X-rays
softX-rays
alpha-particle
HIGH LET
Radiation
LOW LET
Radiation
Separation of ion clusters in relation to
size of biological target
LINEAR ENERGY TRANSFER
LET is average energy (dE) imparted by excitation
and Ionization events caused by a charged particle
traveling a set distance (dl) - LET = dE/dl (keV/ m)
2- Relative biologicaleffectiveness:
*Relative means comparison
*Comparison between standard and variable
*Here the standard is x-ray
Dose of 250 kVp x-rays required to produce an effect
Dose of test radiation required for the same effect
24.
• A doseof 1 Gy will give 2x103
ionization events in 10-10 g (the size
of a cell nucleus). This can be
achieved by:
– 1MeV electrons
•700 electrons which give 6
ionization events per m.
– 30 keV electrons
•140 electrons which give 30
ionization events per m.
– 4 MeV protons
•14 protons which give 300
ionization events per m.
•
The biological effectiveness of
these different radiations vary!
-ray
’-ray
excitation
ionization
particle
excitation and ionization
27.
3-Oxygen Enhancement Ratio(OER)
Why
oxygen
-Binds H radicals forming hydrogen peroxide
H. + O2 HO2
. (+HO2
. ) H2O2 (+O2)
-Binds electrons to give superoxide
e- + O2 O2
- + (H2O) HO2
. + OH-
-Binds organic radicals to form peroxides
R.
+ O2 RO2
. (radical peroxide)
RO2
. + R’ H ROOH + R’ (hydroperoxide)
RO2
. + R’.
ROOR’ (peroxide)
Oxygen “fixes” the radical lesions in DNA in a form that
can not be easily chemically repaired and therefore is a
very powerful radiosensitizer.
28.
Oxygen Enhancement Ratio(OER)
Dose required to produce a specific biological effect in the absence of oxygen
Dose required for the same effect in its presence
=
OER varies with level of effect but
can be 2.5 - 3 fold
1) Culture Cells
(
3) Count cells in hemocytometer
4) irradiate under oxic or hypoxic conditions
0 Gy 2Gy 4Gy 6Gy
5) Plate cells and
grow for about 12 days
. . .
.
.
.
. .
6) Count colonies
Dose (Gy)
S.F.
0 2 4 6 8 10
1.0
0.1
0.01
oxic
hypoxic
2) Suspend Cells
trysinization)
29.
-For low LETradiation the O.E.R. is 2.5-3.0 and in the
higher range at higher doses
- For neutrons, O.E.R is about 1.6
-The oxygen effect is greater for low LET than high
LET radiation
30.
Linear Energy Transfer(LET keV/m)
RBE
(for cell kill)
1000
100
10
1
0
2
4
6
8
RBE
Diagnostic
X-rays
Fast
Neutrons
Alpha
Particles
overkill
0.1
Co-60
gamma rays
0
1
2
3
4
OER
OER
OER is the inverse of RBE because OER depends
considerably on the indirect action of ionizing radiation
RBE is maximal when the average distance between
ionization events = distance between DNA strands =
2nm
RBE and OER as a function of LET
Cytogenetic damage isnormally assessed at first
metaphase after irradiation. The type of cytogenetic
damage depends upon where in the cell cycle the cell is
when it is irradiated
Chromosome aberrations
G1 irradiation
Both sister chromatids involved
Chromatid aberrations
S or G2 irradiation
Usually only 1 chromatid involved
Single lethal hit
Alsoknown as - type killing
4 nm
2 nm
Unrepairable Multiply Damaged Site
It is hypothesized that the lethal
lesions are large double strand
breaks with Multiply Damaged
Sites (MDS) that can not be
repaired. They are more likely
to occur at the end of a track
37.
At high dose,intertrack
repairable Sublethal Damage
may Accumulate forming
unrepairable, lethal MDS
Also known as - type killing
38.
Yield of radiation-inducedchromosome
damage
Exchange-type “lethal” aberrations
≥ 2 hits required or 1 hit required
P (2 hits) = D x D = D2
Y (yield) = k + D2
Y = k + D2
P( 1 hit) = D
Y = D
Y = D + D2
A plot of # “lethal” aberrations vs natural log S.F. showed that an average of
1 lethal lesion decreased survival by e. In other words,
S.F. = e –(D + D2)
39.
Repairable Sublethal Damage
Sub-lethal(or accumulated) damage results from accumulation of events that
individually are incapable of killing a cell but that together can be lethal
4 nm
2 nm
Unrepairable Multiply Damaged Site
42.
Cell Cycle andRadiosensitivity
S.F.
20
16
12
8
4
0
0
.01
.1
1
Dose (Gy)
LATE S
EARLY S
G1 PHASE
G2/M PHASE
Variations in sensitivity and in
cell cycle arrest after irradiation
could be important in radiation
therapy, because fractionated
irradiation can lead to
sensitization by reassortment.
The oxygen enhancement ratio
(OER) does not vary much with
the phase of the cell cycle.
High LET responses are less
affected by cell cycle phase
than low LET radiation
responses.
G1 S G2 M
Increasing
radioresistance
43.
Chromatin Structure andRadiation
Responses
Compact chromatin is more radiosensitive than non-compacted
Mitotic cells
are 2.8 times more sensitive to DNA breaks than interphase
cells ,have a lower OER (eg 2.0 compared with 2.8)
and do not have much of a “shoulder” on their survival
curve
Actively transcribing genes are less sensitive to damage
Radiation Damage to DNA is not randomly distributed.
It varies with cell cycle phase and level of gene expression
Tissue Type
SACUTE RESPONDINGTISSUE LATE RESPONDING TISSUES
(Responses seen during standard
therapy)
Gut
Skin
Bone Marrow
Mucosa
(Responses seen after end of therap
Brain
Spinal Cord
Kidney
Lung
Bladder
46.
Repair of sublethaldamage
spares late responding normal tissue preferentially
Reassortment/Redistribution of cells in the cell cycle
increases acute effects
no influence on late effects
increases damage to tumor
Repopulation/Regeneration
spares acute responding normal tissue preferentially
no influence on late effects,
danger of tumor repopulation
Reoxygenation
no influence on normal tissue responses
increases tumor damage
4Rs OF RADIOBIOLOGY
Latency
*Different tissues takedifferent times to express damage
(latency). This depends on their turnover time.
Defined by the standard 6wks clinical treatment time
49.
0 2 46 8 10 12 14 16 18
Dose (Gy)
BONE
MARROW
Day 30
PERCENT
LETHALITY
GUT
Day 7
LUNG
Day 180
100%
0%
There is no Relationship between
Latency and Tolerance
Different tissues have different tolerances to irradiation and fail at different
times (latency) after irradiation
Latency is determined by cell turnover kinetics in a tissue. It is NOT an
indicator of radiosensitivity.
After moderate doses, gut fails first, then bone marrow, then lung, but the
hematopoietic system is the most radiosensitive
50.
-Intrinsic cellular radiosensitivityand repair
-Regeneration
- Structural organization of tissues
-Wound healing ability
-Non-radiobiologically determined factors, for example
medicolegal, psychological
Tissue Tolerance Doses
51.
In gut, symptomsappear rapidly (2 weeks). This is
the time taken for epithelial cells to traverse the
villus and be shed into the lumen.
Tolerance is about 50 Gy in 2 Gy fx for the small
intestine and slightly higher for the large
intestine.
Lag time before the onset of radiation-induced
proliferation in jejunum may be less than 24
hours. In colon and stomach, slightly longer.
Regeneration and repair
52.
Segment of MouseGut Irradiated with Varying
Doses
12.5Gy 14.0Gy 15.5Gy 17.0Gy
a b c d
XRT
Day 13
Overt tissue response (e.g. ulceration) is dose-dependent with a threshold followed by a rapid
increase in severity.
a. Patchy breakdown of mucosa except in shielded mucosa at top of specimen.
b. Ulcerated mucosa being resurfaced by near-confluent nodules regenerated from a large
number of independently surviving jejunal clonogens.
c. Severe ulceration but with about 60 discrete clonogenically-derived mucosal nodules.
d. As for c. but only 4 regenerated nodules.
53.
Probability of anormal tissue complication
NTCP = 1/(1+(D/ED50)-k
where k is sensitivity - typically about 7 for most normal tissues
ED50 is typically 50-60 Gy
Probability of complication free cure
= [TCP][1-NTCP]
small differences in total dose are
amplified in late responding
tissues, which are more subject to
change with dose per fraction than
are acute effect tissue
54.
Probability
of
damage
(%)
37
0 20 70
60
40
1030 50 80
D10
~ 7.5%
per Gy
90
0
20
80
60
40
100
Small differences in dose can have
major biological effects
Dose (Gy)
Curves for the probability of a normal tissue complication NTCP in
the clinic are generally steep compared with TCP curves
A 20% increase in dose could cause a large increase in the
incidence of complications
55.
Effect of DoseFractionation
on Clonogen Survival in
Jejunum
Repopulation
Redistribution
Repair
Regeneration is a
major factor
contributing to
increased tolerance
of acute responding
tissues during
fractionation
56.
Clinical Relevance ofRegeneration
Mucositis appears 2 to 3 weeks after the start of a standard
RT course.
Regeneration begins at about 10 to 12 days, before evident
mucositis. This can increase the tolerance of the mucosa by
about 1Gy/day, which is equivalent to clonogenic cell
number doubling every 2 days.
57.
Because of regeneration/repopulationin acute, but not late,
normal tissue reactions during treatment:
Protracting overall treatment time beyond the conventional 6
weeks may result in sparing (but tumors may also be spared)
Decreasing overall treatment time to less than the conventional 6
weeks may result in more acute normal tissue reactions
Treatment time has relatively little effect on responses in late
effects tissues
Regeneration/repopulation in late, normal tissue reactions
after treatment, may allow recovery and make retreatment
possible
Clinical Relevance
58.
If the initialdose is close to the
ED50, the remembered dose is
high but if it is 75% of the ED50,
only 25% is ‘remembered’. Mason
et al., Int J Radiat Biol Phys 26:643, 1993
Spinal Cord
Regeneration may be important in recovery of late
responding tissues and retreatment tolerance
Recovery also depends on time
van der Kogel and Fawcett
200
100
0
0
20
40
60
80
100
Time between treatments (days)
50%
initial treatment as % of tolerance
dose
70%
95%
Retreat
ment
ED50 as
a % of
initial
ED50
59.
-The number ofclonogens make up a FSU and their
organization in series or in parallel in a tissue, can
affect “tolerance”
By definition, for an FSU to survive, at least one
clonogen must survive
FSUs can be discrete structures, such as a nephron
in kidney or a liver lobule, or diffuse with no clear
demarcation, eg skin
2-Functional Subunits
60.
168 clonogens in12 FSUs 168 clonogens in 4 FSUs
Which is more radiation resistant and
by how much?
Examples:
Epilation occurs at a lower dose than desquamation - because
hair has fewer clonogenic cells per FSU
Hair depigmentation occurs at a lower dose than skin
depigmentation because follicles contain fewer melanocytes.
61.
FSUs and VolumeEffects
FSUs can be arranged in parallel eg. lung, liver, kidney
In tissues that are intrinsically radiosensitive and rely on a large
functional reserve:
A low dose to a large volume can be hazardous but
A high dose to small volume can be innocuous
This is because function is determined by the amount of tissue
that is not irradiated I.e. the “reserve function determines the
“volume” effect, which will be large.
FSUs can also be arranged in series eg. spinal cord, nerves
In tissues that are intrinsically radioresistant, and where cell migration may
help tissue recovery:
A low dose to a large volume may be innocuous but
A high dose to a small volume may be hazardous
i.e. a strong volume effect over a short distance
This is a ‘true’ volume effect
62.
Two types Tissues
HierarchicalTissues Rich in stem cells and highly proliferative progenito
cells that differentiate into functional differentiated cells. They have a
high turnover rate and a high rate of cell loss. They respond rapidly to
irradiation and fail when the precursor pool fails to generate enough
differentiated cells.
Examples are Gut, Skin, Bone Marrow, Mucosa
Flexible tissues have a slow turnover rate and respond slowly to
irradiation. They fail when there is enough cell loss to induce
regeneration, which triggers an avalanche of cell death, generally
after a long lag period.
Examples are Brain, Spinal Cord, Kidney, Lung, Bladder
63.
Late Effects areComplex
For example:
Lung expresses damage in two major waves -
pneumonitis and fibrosis.
In mice, these vary with the strain and are
genetically determined
In brain, demyelination with white matter
necrosis, edema, hemorrhagic necrosis, and
atrophy are variably found.
64.
Conclusions
The time toa normal tissue complication depends on the tissue turnover time.
It is relatively independent of dose for hierarchical, but not flexible, tissues
The time to and extent of regeneration in normal tissues also determines how
much dose can be tolerated
Tissue tolerance depends not only on intrinsic radiosensitivity of clonogens, but
also on organization into FSUs, and the number of clonogens per FSU
Volume effects are complex, but a major volume effect may be due to
differences in FSU organization
Late effects are complex, but there is some reason to think they may, to an
extent, be reversible. The balance of cytokines and growth factors
determine both regeneration and normal tissue complications
•
*Objectives:
1- Reirradiation ofHead and neck.
2- Reirradiation of recurrent brain tumors.
3- Reirradiation of painful bone metastasis.
68.
• Last decadewitnessed major progress in management of pts with HNSCC
due to
– The addition of concomitant chemotherapy
– Significant improvement in radiation techniques (IMRT)
However,
Vast majority of these occur in previously irradiated areas and thus poses a
common challenge to H & N oncologists
Reirradiation of Head and neck
69.
Treatment options forRecurrent HNC
Resectable / Unresectable
Resectable Unresectable
-
Traditionally a std of care for
resectable tumour
-
However only 20 % pts are
candidates for curative
resection
-
Results of salvage surgery are
poor
-
Poor response rates
-
Limited palliation and
-
No long term survival
-
Nearly all pts die of disease
progression within months
- Historically been avoided owing to concerns regarding
toxicity
- Radiation tolerance of the normal tissue is significantly
reduced compared with the first treatment
- However, more recently published data
demonstrated the feasibility and effectiveness of
reirradiation
Re irradiation
Surgery Palliative
Chemotherapy
70.
• Most recurrencesare local and in field.
• Mostly in high dose regions.
• Distant mets incidence increases if both primary and
nodal failure occurs.
71.
• Patients shouldbe carefully selected:
– Favourable sites such as larynx and nasopharynx;
– Small tumour size (< 3cm);
– A relatively longer period since previous irradiation
(preferably ≥6 months);
– No major late complications due to initial RT.
72.
• PET CTbased planning may be required as it may be
difficult to distinguish fibrosis and recurrent tumor on
CT/MRI.
• RT dose fractionation not > 2 Gy/#.
• Incidence of soft tissue necrosis- 0 to 40%
• Pt. nutrition- should be excellent
73.
• Re irradiationdose should be more than 58 Gy for better LRC, PFS and
OS, in many studies (OS- 30% vs 6%)
• Cumulative dose to target volume should be more than 100Gy (Either alone
or combined with CT).
• Cumulative RT dose not more than 130Gy @ 2Gy/#.
• Radiation fields should be small.
• Highly conformal techniques are usually required- IMRT, SRS, SRT, etc.
• CTV should include only GTV and limited margins (1.5 to 2cm) or high risk
areas – positive surgical margins or lymph nodes with extra nodal spread.
74.
• Cumulative dose– subcutaneous tissue= 110Gy ,
spinal cord= 50Gy.
• More than 90% of the initial dose can be given to subcutaneous
tissues after 6 weeks of initial radiation.
• 60% of the initial dose effect is repaired by the spinal cord if
treatment courses are separated by 1–3 years.
• Risk of myelitis < 6% if # size – 1.8 to 2.0 Gy.
75.
• Better responseand OS if overall cumulative field of RT
<125 cm2.
• More reactions expected if cumulative field of irradiation
> 70 cm2.
• 2 year loco regional control rate-
– 52% with IMRT
– 20% with conventional 2D RT.
76.
Strictly involved fieldradiotherapy
No elective nodal irradiation
No elective Clinical Target volumes
Target volume delineation
77.
• Mucositis ratesincrease by 30%
• Severe late reactions- 1 year
• Severe late reaction rate- 9 to 41% (mean 25%)
• Speech is preserved ,swallowing function is the concern.
• Males more tolerant to side effects
• Most severe reactions in age > 80 years
78.
• Severe latetoxicities (0 to 48%) – 6 mths to yrs.
• Endocrine dysfunction,
• Dysphagia,
• Trismus,
• Decreased hearing,
• Osteonecrosis, and
• Chondronecrosis.
• Fatal complications (0 to 16%)
• Carotid artery rupture,
• Brain necrosis,
• Aspiration due to cranial nerve paralysis,
• Pharyngeal dysmotility, and
• Narcotic overdose
79.
2- Reirradiation ofpainful bone metastasis
• Bone metastases are common manifestation in
malignancy
• It causes – Pain
Spinal Cord Compression
Hypercalcemia
Fractures
• Multidisciplinary Management is required
80.
1) When shouldpatients receive re-treatment with
radiation to peripheral bone metastases?
• Rates of re-treatment - 20% with single fraction
as compared 8%with lengthier courses of
treatment.
• Normal tissue tolerance – limiting factor.
• The presence of persistent pain in weight bearing
or long bones would necessitate a re-assessment
of pathologic fracture risk.
81.
2) When shouldpatients receive re-treatment with
radiation to spine lesions causing recurrent pain?
• Sites of recurrent pain in spine bones - palliated
with EBRT re-treatment, but no conclusive data
regarding dosing and fractionation.
• If the re-irradiated volume contains the spinal
cord, sum of the BEDs of earlier RT to estimate
the risk of radiation myelopathy.
82.
• Few retrospectivesstudies - good pain control with a
limited risk of side effects following re-irradiation with
single fractions between 4 Gy and 8 Gy.
• Radiation myelopathy - 3% when :
1. Sum of two BEDs – 135.5 Gy (a/b = 2Gy for spine,
according to LQ model)
2. Neither single course BED > 98 Gy.
3. Interval not less than 6 months
83.
3) What promisedoes highly conformal radiotherapy
hold for the primary treatment of painful bone
metastasis?
• Stereotactic body radiation therapy (SBRT).
• Dosage and target delineation yet to be fully
defined
• Given under clinical trials and should not be the
primary treatment of vertebral bone lesions causing
spinal cord compression.
84.
• Aims atidentifying who may achieve more
durable pain relief or overall failure-free survival
with SBRT.
• Late toxicities can occur such as :
o Radiation myelopathy – in previously untreated
patients
o New or progressive vertebral compression
fractures
o Esophageal and bronchial problems
85.
4) When shouldhighly conformal radiotherapy be
considered for re-treatment of spine lesions
causing recurrent pain?
• No definitive data to specify the proper patient
selection criteria.
• Re-treatment to spine lesions with SBRT may be
feasible, effective, and safe.
• Limited to the setting of clinical trial participation
• No evidence of superiority of SBRT over
conventional EBRT with respect to pain control.
• May lead to unexpected side effect risks.
86.
3-Reirradiation of recurrentbrain tumors.
*The current standard of care for glioblastoma multiforme (GBM) is
radiotherapy with concurrent and adjuvant temozolomide.
*This is associated with a5-year overall survival of 9.8% versus 1.9%
with radiotherapy alone.
*Because of the infiltrating nature of gliomas, they frequently recur
and despite an increase in survival rates the majority of patients
progress within 1–2 years.
*With regards to anaplastic astrocytomas and low grade gliomas the
time to local recurrence is longer, but the majority ultimately also
recur.
87.
*Salvage therapy isindicated in the majority of recurrent gliomas,
and most patients receive chemotherapy or surgery at relapse
*Re-irradiation for brain tumours is now attracting more interest
as our understanding of the tolerance of the brain evolves.
*Developments in radiation technology and imaging also mean
that highly accurate targeting of biologically relevant
tumour volumes is possible.
88.
The Biology ofLate Central Nervous System
Toxicity:
CNS toxicity following irradiation has been divided into three phases:-
1-early (days–weeksafter),
2-early delayed (1–6 months after and includes somnolence syndrome
and Lhermitte’s phenomenon due to transient demyelination)
3-late (greater than 6 months following irradiation).
Early and early delayed toxicities are normally reversible and
spontaneously resolve whereas late toxicity is normally
progressive and irreversible.
Late injury is characterised pathologically by demyelination, vascular
changes and ultimately necrosis
89.
Evidence for Re-irradiationusing various techniques
1-Conformal Radiotherapy
3D conventional radiotherapy using co-registered magnetic
resonance imaging (MRI) has improved target definition and
allows for a reduction of the dose to normal structures.
Further developments such as IMRT (intensity-modulated
radiotherapy) can improve this further by conformality at the
target using multiple-modulated beams.
For re-irradiation, the aim is not only to treat the area of
recurrence with an adequate margin, but also to reduce as much
as possible the total dose to critical organs at risk within the CNS,
as, optic nerves or brainstem, making highly conformal
90.
CT and MRI-fusedplanning images for a patient treated for a recurrent glioma.
10 years previously treated with 55 Gy in 30 fractions over 6 weeks. Re-irradiated
with 30 Gy in 6 fractions over 2 weeks. CTV contrast enhancing volume on
T1-weighted MRI. PTV = CTV ? 0.5 cm margin
2-Stereotactic Radiosurgery/Fractionated Stereotactic
Radiotherapy:-
Stereotacticradiosurgery (delivered using the Leksell Gamma Knife,
adapted linear accelerators, Cyber Knife and other devices) is a non-
invasive, highly conformal radiotherapy technique.
It allows very accurate dose delivery with the patient in a fixed head
frame and multiple beam sources producing a steep dose gradient
at the edge of the target, therefore allowing a highly precise dose to
be delivered to tumour whilst sparing the surrounding normal tissues
and organs at risk.
93.
57-year-old patient withrecurrent glioblastoma of theright temporal lobe anterior to the
surgical resection cavity. The targeted volume was 12.3 ml. The patient was treated with
SRS to a dose of 18 Gy prescribed to the 90% isodose line
94.
3-Brachytherapy
Most studies inthe brain have used 125I or 192I.
Placement of multiple sources of radiation around
the surgical cavity is technically challenging to ensure
an adequate and even dose distribution.
95.
Dose and delineation
Mostrecurrent glioma patients will have received the equivalent
of 55–60 in 1.8–2 Gy per fraction when they were initially treated,
and therefore not more than 40 Gy equivalent in a
hypofractionated regimen should be delivered when re-
irradiating, aiming to keep the total dose less than 100 Gy
To optimise the outcome of radiotherapy treatment, improved target
definition is of paramount importance. In this context, alternative
biological imaging may improve the definition of the relevant target;
for example, Amino Acid PET (SPECT)/CT/MRI image fusion to
determine the gross tumour volume are currently under investigation.